1
|
Ahmed S, Keniry M, Anaya-Barbosa N, Padilla V, Javed MN, Gilkerson R, Narula AS, Ibrahim E, Lozano K. Oxymatrine Loaded Cross-Linked PVA Nanofibrous Scaffold: Design and Characterization and Anticancer Properties. Macromol Biosci 2023; 23:e2300098. [PMID: 37270675 DOI: 10.1002/mabi.202300098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Revised: 05/08/2023] [Indexed: 06/05/2023]
Abstract
This study focuses on the fabrication, characterization and anticancer properties of biocompatible and biodegradable composite nanofibers consisting of poly(vinyl alcohol) (PVA), oxymatrine (OM), and citric acid (CA) using a facile and high-yield centrifugal spinning process known as Forcespinning. The effects of varying concentrations of OM and CA on fiber diameter and molecular cross-linking are investigated. The morphological and thermo-physical properties, as well as water absorption of the developed nanofiber-based mats are characterized using microscopical analysis, energy dispersive X-ray spectroscopy, Fourier transform infrared spectroscopy, differential scanning calorimetry, and thermogravimetric analysis. In vitro anticancer studies are conducted with HCT116 colorectal cancer cells. Results show a high yield of long fibers embedded with beads. Fiber average diameters range between 462 and 528 nm depending on OM concentration. The thermal analysis results show that the fibers are stable at room temperature. The anticancer study reveals that PVA nanofiber membrane with high concentrations of OM can suppress the proliferation of HCT116 colorectal cancer cells. The study provides a comprehensive investigation of OM embedded into nanosized PVA fibers and the prospective application of these membranes as a drug delivery system.
Collapse
Affiliation(s)
- Salahuddin Ahmed
- Department of Mechanical Engineering, University of Texas Rio Grande Valley, Edinburg, TX, 78539, USA
| | - Megan Keniry
- Department of Biology, The University of Texas Rio Grande Valley, Edinburg, TX, 78539, USA
| | - Narcedalia Anaya-Barbosa
- Department of Mechanical Engineering, University of Texas Rio Grande Valley, Edinburg, TX, 78539, USA
| | - Victoria Padilla
- Department of Mechanical Engineering, University of Texas Rio Grande Valley, Edinburg, TX, 78539, USA
| | - Md Noushad Javed
- Department of Mechanical Engineering, University of Texas Rio Grande Valley, Edinburg, TX, 78539, USA
| | - Robert Gilkerson
- Department of Biology, The University of Texas Rio Grande Valley, Edinburg, TX, 78539, USA
| | | | - Eman Ibrahim
- Department of Mechanical Engineering, University of Texas Rio Grande Valley, Edinburg, TX, 78539, USA
| | - Karen Lozano
- Department of Mechanical Engineering, University of Texas Rio Grande Valley, Edinburg, TX, 78539, USA
| |
Collapse
|
2
|
Neumaier F, Zlatopolskiy BD, Neumaier B. Drug Penetration into the Central Nervous System: Pharmacokinetic Concepts and In Vitro Model Systems. Pharmaceutics 2021; 13:1542. [PMID: 34683835 PMCID: PMC8538549 DOI: 10.3390/pharmaceutics13101542] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2021] [Revised: 09/17/2021] [Accepted: 09/20/2021] [Indexed: 12/22/2022] Open
Abstract
Delivery of most drugs into the central nervous system (CNS) is restricted by the blood-brain barrier (BBB), which remains a significant bottleneck for development of novel CNS-targeted therapeutics or molecular tracers for neuroimaging. Consistent failure to reliably predict drug efficiency based on single measures for the rate or extent of brain penetration has led to the emergence of a more holistic framework that integrates data from various in vivo, in situ and in vitro assays to obtain a comprehensive description of drug delivery to and distribution within the brain. Coupled with ongoing development of suitable in vitro BBB models, this integrated approach promises to reduce the incidence of costly late-stage failures in CNS drug development, and could help to overcome some of the technical, economic and ethical issues associated with in vivo studies in animal models. Here, we provide an overview of BBB structure and function in vivo, and a summary of the pharmacokinetic parameters that can be used to determine and predict the rate and extent of drug penetration into the brain. We also review different in vitro models with regard to their inherent shortcomings and potential usefulness for development of fast-acting drugs or neurotracers labeled with short-lived radionuclides. In this regard, a special focus has been set on those systems that are sufficiently well established to be used in laboratories without significant bioengineering expertise.
Collapse
Affiliation(s)
- Felix Neumaier
- Institute of Radiochemistry and Experimental Molecular Imaging, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany; (B.D.Z.); (B.N.)
- Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Wilhelm-Johnen-Str., 52428 Jülich, Germany
| | - Boris D. Zlatopolskiy
- Institute of Radiochemistry and Experimental Molecular Imaging, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany; (B.D.Z.); (B.N.)
- Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Wilhelm-Johnen-Str., 52428 Jülich, Germany
| | - Bernd Neumaier
- Institute of Radiochemistry and Experimental Molecular Imaging, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany; (B.D.Z.); (B.N.)
- Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Wilhelm-Johnen-Str., 52428 Jülich, Germany
| |
Collapse
|
3
|
Chen Q, Zhou H, Yang Y, Chi M, Xie N, Zhang H, Deng X, Leavesley D, Shi H, Xie Y. Investigating the potential of Oxymatrine as a psoriasis therapy. Chem Biol Interact 2017; 271:59-66. [PMID: 28450041 DOI: 10.1016/j.cbi.2017.04.020] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2016] [Accepted: 04/24/2017] [Indexed: 12/29/2022]
Abstract
Psoriasis vulgaris is a chronic inflammatory skin disease, stubbornly intractable, with substantial consequences for patient physical and mental welfare. Approaches currently available to treat psoriasis are not satisfactory due to undesirable side-effects or expense. Psoriasis is characterized by hyperproliferation and inflammation. Oxymatrine, an active component extracted from Sophora flavescens, has been demonstrated to possess anti-proliferation, anti-inflammatory, anti-tumorigenic, immune regulation and pro-apoptotic properties. This investigation presents a detailed retrospective review examining the effect of Oxymatrine on psoriasis and investigates the mechanisms underlying patient responses to Oxymatrine. We confirm that Oxymatrine administration significantly reduced the Psoriasis Area Severity Index score, with high efficacy compared to the control group. In addition, we have found that Oxymatrine significantly inhibits the viability, proliferation and differentiation of human keratinocyte in vitro. Immunohistochemical analysis indicates Oxymatrine significantly suppresses the expression of Pan-Cytokeratin, p63 and keratin 10. The results indicate that the suppression of p63 expression may lead to the anti-proliferation effect of Oxymatrine on human skin keratinocytes. Oxymatrine does not affect the formation of basement membrane, which is very important to maintain the normal function of human skin keratinocytes. In summary, Oxymatrine offers an effective, economical, and safe treatment for patients presenting with intractable psoriasis vulgaris.
Collapse
Affiliation(s)
- Qian Chen
- Ningxia Medical University, Ningxia, China
| | - Hui Zhou
- Department of Dermatology, General Hospital of Ningxia Medical University, Ningxia, China
| | - Yinxue Yang
- President of General Hospital of Ningxia Medical University, Ningxia, China
| | - Mingwei Chi
- Medical Affairs Office, General Hospital of Ningxia Medical University, Ningxia, China
| | - Nan Xie
- Tissue Organ Bank & Tissue Engineering Centre, General Hospital of Ningxia Medical University, Ningxia, China
| | - Hong Zhang
- Tissue Organ Bank & Tissue Engineering Centre, General Hospital of Ningxia Medical University, Ningxia, China
| | | | - David Leavesley
- Tissue Organ Bank & Tissue Engineering Centre, General Hospital of Ningxia Medical University, Ningxia, China; Tissue Technologies, Institute of Medical Biology, Agency for Science, Technology and Research, Singapore; Skin Research Institute of Singapore, Agency for Science, Technology and Research, Singapore; School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Australia; Lee Kong Chain School of Medicine, Nanyang Technological University, Singapore
| | - Huijuan Shi
- Department of Dermatology, General Hospital of Ningxia Medical University, Ningxia, China.
| | - Yan Xie
- Tissue Organ Bank & Tissue Engineering Centre, General Hospital of Ningxia Medical University, Ningxia, China; School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Australia.
| |
Collapse
|